OMER
Omeros Corporation · Healthcare · Biotechnology
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2024
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 30.11K | $575,627 | +1 | −1 |
| Q2 2026 | 74 | -1 | 26.77M | $254.67M | +8 | −10 |
| Q1 2026 | 78 | +7 | 23.56M | $249.21M | +9 | −2 |
| Q4 2025 | 71 | -2 | 30.19M | $466.97M | n/a | −2 |
| Q3 2025 | 17 | 0 | 17.59M | $72.13M | n/a | n/a |
| Q2 2025 | 14 | +1 | 14.04M | $42.12M | +1 | n/a |
| Q1 2025 | 10 | +1 | 6.15M | $50.54M | +1 | n/a |
| Q4 2024 | 9 | 0 | 4.83M | $47.77M | +1 | −1 |
| Q3 2024 | 8 | +1 | 3.34M | $13.26M | +1 | n/a |
| Q2 2024 | 7 | n/a | 3.21M | $13.02M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | D. E. Shaw & Co. ✦ | 1.58M | n/a | $6.40M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (被动) | 1.33M | n/a | $5.41M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Two Sigma Investments ✦ | 159.45K | n/a | $647,351 | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 61.58K | n/a | $250,003 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 35.18K | n/a | $143,000 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 25.80K | n/a | $104,748 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | Millennium Management ✦ | 16.97K | n/a | $68,910 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 1 持有人, 4.17M 股份, $8.90M 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer · 10.00K 股 · $209,500
Officer · 10.00K 股 · $209,500
Officer · 25.00K 股 · $463,540
Officer · 25.00K 股 · $466,128
Director · 5.00K 股 · $94,381
Director · 5.00K 股 · $95,080
Director · 5.00K 股 · $92,632
Officer · 906 股 · $17,305
Officer · 10.00K 股 · $189,500
Director · 15.00K 股 · $276,772
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论